Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
Osteoporosis
NAMS Updates Position Statement on Osteoporosis Management
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Experts Address Osteoporosis Therapy and COVID-19 Vaccination
Oral bisphosphonates should be continued without delay; one-week interval recommended between IV bisphosphonate and vaccine
Rates of Drug Treatment for Osteoporosis Low in the US
Patterns of drug prescribing for the treatment of osteoporosis often do not follow clinical practice guidelines
Topical Corticosteroid Use and Osteoporosis Risk Examined
To determine the association between cumulative exposure of potent and very potent TCSs and osteoporosis and MOF risk, study authors utilized the Danish nationwide registries.
Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
Osteoporotic Fracture Risk Lower for DOAC Than Warfarin in A-Fib
No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
Societies Issue Joint Guidance for Osteoporosis Management During the COVID-19 Pandemic
A coalition of experts representing multiple medical societies issued guidance on the management of osteoporosis during the COVID-19 pandemic.
Endocrine Society Updates Postmenopausal Osteoporosis Management Guidelines to Include Romosozumab
The Endocrine Society has issued an update to the organization’s 2019 clinical practice guideline on pharmacologic management of osteoporosis to include romosozumab.
Fracture Risk, BMD Improvement With Abaloparatide Plus Alendronate in Osteoporosis, OA
In this post hoc analysis, researchers evaluated the efficacy and safety of abaloparatide followed by alendronate vs placebo followed by alendronate in a subgroup of patients with osteoarthritis.
